INTEGRATIVE PEPTIDES TB4-FRAG

$130.00 or subscribe and save up to 5%

SKU: TB4-FRG-INT Categories: ,

Description

 

Integrative Peptides' TB4-FRAG™ contains the active fragment of the larger peptide Thymosin Beta 4.

Purpose to stimulate and support healing

1 bottle contains 60 Thymosin Beta 4 capsules

Ingredients: Thymosin Beta 4 Active Fragment 250mcg, d-ribose 25mg, other ingredients: microcrystalline cellulose, delayed release veggie capsule.

Instructions

One capsule, two times a day.

Vegan - Non-GMO - Made in USA

What is the content and potency of Thymosin Beta 4?

Integrative Peptides’ TB4-FRAG contains the active fragment of the larger peptide Thymosin Beta 4. Each bottle consists of 60 capsules, with the Thymosin Beta 4 Active Fragment dosed at 250mcg per capsule. Additionally, the formulation includes d-ribose at 25mg. This product is packaged in delayed-release veggie capsules with other ingredients such as microcrystalline cellulose. The Thymosin Beta 4 Active Fragment in TB4-FRAG offers a specific and precise dosage for targeted administration.

What are the potential uses of Thymosin Beta 4 in treating various conditions?

Thymosin Beta 4 has a wide range of potential uses in treating various conditions:

1. Arthritis: Thymosin Beta 4 shows effectiveness in addressing inflammatory conditions by targeting inflamed tissues and aiding in joint inflammation reduction to improve mobility.

2. Blood Clots: It has been discovered that Thymosin Beta 4 can effectively treat blood clots and stimulate the growth of new blood cells.

3. Soft Tissue Damage: Injuries to muscles, tendons, and ligaments can benefit from Thymosin Beta 4 as it aids in quicker repair and may help in reducing scar tissue formation.

4. Diseases: Thymosin Beta 4 exhibits potential in treating autoimmune diseases, infections, Lyme disease, and traumatic brain injuries.

5. Muscular Health: Thymosin Beta 4 supports muscle repair and growth, and can assist in controlling muscle spasms.

6. Cardiovascular or Neurological Damage: Thymosin Beta 4 plays a role in promoting new blood vessel formation, fostering neuron formation, and enhancing axonal density in the brain.

7. The claim that thymosin beta 4 promotes hair growth is supported by various studies and experiments. For instance, research conducted on rats has shown that thymosin beta 4 facilitates hair growth by enhancing the hair follicle cycle and encouraging the migration of stem cells toward the follicle base. Additionally, studies on mice have demonstrated that thymosin beta 4 impacts the growth of blood vessels surrounding hair follicles through the regulation of vascular endothelial growth factor (VEGF). Further evidence from rat and mouse models indicates that thymosin beta 4 plays a role in stimulating follicle stem cell growth and migration, leading to increased hair growth. Moreover, clinical trials involving patients with alopecia areata, an autoimmune condition causing hair loss, have shown that thymosin beta 4 treatment over 3 months reduced the severity of the disease and prompted notable hair regrowth.

8. Thymosin beta 4 may have a positive impact on blood pressure through its potential effects on immune function. Research suggests that thymosin beta 4 administration could lead to the growth of T cells, which may help reduce autoimmune activity. By decreasing the autoimmune response, it is theorized that thymosin beta 4 could potentially contribute to lowering blood pressure in mammals.

9. Thymosin beta 4 aids in enhancing lung health by leveraging its anti-scarring properties to combat lung damage. Specifically, when administered in mice with bleomycin-induced lung damage, thymosin beta 4 works to suppress inflammation and prevent scarring in the lungs. This proactive approach not only helps maintain lung tissue integrity but also contributes to overall lung health improvement. Moreover, thymosin beta 4 showcases its ability to normalize blood sugar levels by playing a dual role in safeguarding against diabetes-related nerve injuries and stabilizing blood glucose concentrations. Through its actions in diabetic mice, thymosin beta 4 efficiently mitigates high blood sugar levels (hyperglycemia) and enhances insulin sensitivity. By doing so, this peptide fosters a more balanced blood sugar profile and aids in managing diabetes-related glycemic imbalances effectively.

10. Thymosin beta 4 has been shown in various studies to play a critical role in promoting brain health, particularly in cases of stroke and other brain injuries. Research has indicated that thymosin beta 4 may aid in safeguarding against stroke and brain injuries by stimulating the regeneration and formation of new blood vessels. In animal studies, it has been found that thymosin beta 4 treatment significantly improved neurological functional outcomes in cases of ischemic stroke. Administering thymosin beta 4 in rat models of stroke has been shown to enhance oligodendrogenesis, a process crucial for repairing and protecting nerve cells. Furthermore, thymosin beta 4 treatment in patients with stroke and other neurological conditions seems to facilitate the remodeling and reconstruction of the nervous system by activating self-healing mechanisms in the brain, spinal cord, and nerves. Moreover, in animal models of traumatic brain injury (TBI), early administration of thymosin beta 4 has demonstrated the potential to reduce brain lesions and cell loss while enhancing functional recovery. These findings collectively suggest that thymosin beta 4 plays a vital role in promoting brain health and recovery from various brain injuries, including stroke.

11. Thymosin beta 4 contributes to improving eye health by reducing levels of proinflammatory substances and promoting rapid healing in corneal injuries, such as diabetic corneal defects. Additionally, it helps in relieving symptoms of dry eye by alleviating related signs. In terms of nerve regeneration, thymosin beta 4 aids in functional recovery by reducing inflammation and promoting the generation of oligodendrocytes in conditions like brain inflammation, spinal cord injury, and multiple sclerosis. Moreover, it plays a vital role in stem cell maturation and the repair of nerve injuries, showing promise in enhancing nerve regeneration processes.

12. Thymosin beta 4 improves liver health through various mechanisms. Firstly, it suppresses the activation of hepatic stellate cells (HSCs), which play a key role in liver fibrosis, thereby preventing scarring. Additionally, thymosin beta 4 possesses anti-inflammatory and anti-scarring properties that protect the liver from damage. Furthermore, it stimulates liver regeneration by facilitating cell migration, blood vessel formation, cell survival, and the maturation of stem cells. In cases of chronic hepatitis B and non-alcoholic fatty liver disease (NAFLD), thymosin beta 4 reduces oxidative stress and proinflammatory factors. Moreover, it inhibits the production of substances that contribute to liver scarring, further promoting liver health.

13. Research on Thymosin Beta 4 has shown various important findings across different studies. It has been observed to have anti-inflammatory properties as it suppresses proinflammatory cytokines like interleukin 8 (IL8) and protects against cell death. Additionally, it has been found to modulate the function of lymphocytes in the human colon and inhibit white blood cell infiltration while reducing pro-inflammatory cytokine levels in a murine model. Thymosin Beta 4 has also been associated with facilitating the recognition of harmful microorganisms, promoting the production of hemocytes crucial for the immune system in invertebrates, and exhibiting antiviral properties. Moreover, it enhances the binding ability of antibodies with antigens, boosts natural killer cell activity, and is involved in the engulfment of cells triggering apoptosis. In clinical trials, Thymosin Beta 4 has shown promise in the treatment of primary immunodeficiency diseases, autoimmune diseases, and cancer by maintaining immune balance and preventing thymus gland malfunction. Additionally, research has indicated the antibacterial effects of Thymosin Beta 4 against specific pathogens like Pseudomonas aeruginosa.

15. Thymosin beta 4 is released by your body’s platelets, macrophages, and various other cell types in response to injury. Once released, it works to protect your tissues and cells from additional damage. It also reduces inflammation, microbial growth, and apoptosis (the death of cells). This protective role of thymosin beta 4 is crucial in the initial stages of wound healing. Moreover, thymosin beta 4 plays a significant role in the acceleration of wound healing through various mechanisms. When released, it binds to actin and promotes the differentiation, mobilization, and migration of stem and progenitor cells. By facilitating these processes, thymosin beta 4 supports tissue regeneration by aiding in the formation of new blood vessels and the migration of cells to the injured area. These actions contribute to the overall speed and efficiency of the healing process. In addition to promoting cell regeneration, thymosin beta 4 also assists in reducing the number of myofibroblasts in wounds. This reduction leads to decreased fibrosis and scar formation, ultimately resulting in improved tissue repair and cosmetic outcomes. The ability of thymosin beta 4 to modulate these cellular processes highlights its multi-faceted role in accelerating wound healing and underscores its potential as a therapeutic agent for various types of injuries.

16. Thymosin beta 4 is a water-soluble peptide that naturally occurs in the body. As a peptide, it’s a string of amino acids, which are the building blocks of proteins and the body. Thymosin beta 4 is a key player in repairing and regenerating injured cells and tissues. It’s also highly conserved and is the most abundant thymic peptide. Aside from red blood cells, this peptide is found in all of the body’s tissues and cell types. Furthermore, Thymosin beta 4 plays a crucial role in the training and development of T cells, a special type of white blood cell, and assists in the production of antibodies essential for maintaining a strong immune system. This multi-functional protein also aids in facilitating muscle and cell movement, contributing to tissue regeneration and protection. Moreover, Thymosin beta 4's ability to increase the number of immune system cells while decreasing inflammatory substances is noteworthy. By binding to actin, it promotes the migration and mobilization of stem/progenitor cells, which support angiogenesis and stimulate tissue regeneration. Additionally, Thymosin beta 4 helps in reducing scar formation by limiting the presence of myofibroblasts, cells responsible for wound healing and tissue repair, in wounds.

Furthermore, Thymosin Beta 4 offers ancillary benefits such as calming muscle spasms, enhancing muscle tone, facilitating substance exchange between cells, encouraging tissue repair, maintaining flexibility, reducing joint tissue inflammation, promoting new blood cell growth, boosting endurance and strength, and preventing fibrous band formation in muscles, tendons, and ligaments.

What benefits does Thymosin Beta 4 have?

Thymosin Beta 4 can relate to the reader by offering a wide range of benefits that may apply to various individuals. For example, this peptide is commonly used by people seeking to accelerate injury recovery or improve muscle tone and stamina. Athletes may find it particularly useful to speed up healing processes before important events. Additionally, Thymosin Beta 4 can aid in muscle development, enhance flexibility, reduce inflammation in joints, promote tissue repair, and prevent the formation of scar tissue. It can also be beneficial for treating conditions such as arthritis, blood clots, soft tissue damage, autoimmune diseases, infections, and muscular or neurological damage. Overall, this peptide provides a comprehensive approach to improving physical health and well-being, making it relevant to readers interested in enhancing their muscle repair, flexibility, endurance, and overall body function.

What is the content and potency of Thymosin Beta 4?

Integrative Peptides’ TB4-FRAG contains the active fragment of the larger peptide Thymosin Beta 4. Each bottle consists of 60 capsules, with the Thymosin Beta 4 Active Fragment dosed at 250mcg per capsule. Additionally, the formulation includes d-ribose at 25mg. This product is packaged in delayed-release veggie capsules with other ingredients such as microcrystalline cellulose. The Thymosin Beta 4 Active Fragment in TB4-FRAG offers a specific and precise dosage for targeted administration.

Should TB4-FRAG be taken with or without food?

The oral peptide products are gastric stable and can be taken with or without food. Some reports, however, indicate that absorption of supplements is better on an empty stomach.

Is TB4-FRAG bioavailable?

The bioavailability of Integrative Peptides supplements reflects the comprehensive research and manufacturing efforts that have been undertaken to ensure their efficacy and absorption within the body. While acknowledging that intravenous or intramuscular injection may offer higher bioavailability compared to oral administration, the dosing of Integrative Peptides supplements has been tailored to deliver therapeutic benefits effectively. This approach aims to provide a convenient and efficient solution while maintaining transportability and ease of use without the need for injection.

Can TB4-FRAG be used in Pregnant and Nursing Women? What about for Children?

We do not endorse the use of this product in anyone who is pregnant, may become pregnant, or nursing. Furthermore, we do not endorse the use of this product for anyone under 18 years of age. Please consult with your physician for further information.

What is the bottom line regarding the benefits of Thymosin Beta 4 and the importance of consulting healthcare providers before use?

Thymosin Beta 4 acts as an active peptide that enhances the immune system while also supporting muscle strength, tissue health, and overall defense mechanisms. It is important to consult with healthcare providers before considering its use to ensure compatibility with any current medications and to prevent potential complications.

Is Integrative Peptides' TB4-FRAG FDA approved?

Supplements are not approved by the FDA. We are FDA registered and follow all Good Manufacturing Process guidelines in addition to independent third-party testing for purity, heavy metals, microbials, and other contaminants.

Where is TB4-FRAG manufactured?

All our products are made in the USA.

Do I have to keep TB4-FRAG refrigerated?

TB4-FRAG is designed to be shelf stable and do not need to be refrigerated. However, to ensure optimal potency and shelf-life, you should limit exposure of Thymosin Beta 4 capsules to extreme heat and cold.

When can I expect my TB4-FRAG order?

All orders are usually processed with tracking information within the next business day.

Do the supplements from Integrative Peptides contain gluten, dairy, soy, or magnesium stearate?

The supplements from Integrative Peptides do not contain gluten, dairy, soy, or magnesium stearate. The company emphasizes the importance of clean products and hopes that customers appreciate this quality in their supplements.

What are the reported side effects of Thymosin Beta 4?

Reported side effects of Thymosin Beta 4 include experiencing reddening, pain, and discomfort at the injection site, particularly when larger needles are used. Additionally, individuals may feel tired or lethargic after taking this peptide. Some people may also experience a headache or head rush, especially during their initial injection of Thymosin Beta 4.

How can customers stay informed about new information and products from Integrative Peptides?

Customers can stay informed about new information and products from Integrative Peptides by subscribing to the company's newsletter on their website. Through this newsletter subscription, customers will receive the latest articles and updates, offering valuable information to enhance their understanding of peptides and supplements. Additionally, customers are encouraged to check the website frequently for the most up-to-date information on products and services available, ensuring that they are always well-informed about what Integrative Peptides has to offer.

Want to learn more about the TB4-FRAG order?

Check out the latest Blog article on TB4-Frag Peptide: How Thymosin Beta 4 Supports Vital Healing and Recovery

Always work with your primary care physician or schedule a consultation with one of our naturopathic doctor online.

References

  1. Reti R, Kwon E, Qiu P, Wheater M, Sosne G. Thymosin beta4 is cytoprotective in human gingival fibroblasts. European journal of oral sciences. 2008; 116(5):424-30. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/18821984.
  2. Elitsur Y, Mutchnick MG, Sakr WA, Luk GD. Thymosin alpha 1 and thymosin beta 4 modulate human colonic lamina propria lymphocyte function. Immunopharmacology. ; 20(2):89-96. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/2266003.
  3. Sosne G, Chan CC, Thai K, et al. Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Exp Eye Res. 2002;74:293–9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11950239.
  4. Bubb MR. Thymosin beta 4 interactions. Vitamins and hormones. 2003; 66:297-316. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/12852258.
  5. Li J, Zhang Y, Liu Y. A thymosin beta-4 is involved in production of hemocytes and immune defense of Hong Kong oyster, Crassostreahongkongensis. Developmental and comparative immunology. 2016; 57:1-9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/26695126.
  6. Retrieved from https://www.sciencedirect.com/science/article/pii/S0145305X15000713.
  7. Retrieved from http://onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.2012.06659.x/abstract.
  8. Lee HR, Yoon SY, Kang HB. Thymosin beta 4 enhances NK cell cytotoxicity mediated by ICAM-1. Immunology letters. 2009; 123(1):72-6. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/19369144.
  9. Lee SJ, So IS, Park SY, Kim IS. Thymosin beta4 is involved in stabilin-2-mediated apoptotic cell engulfment. FEBS letters. 2008; 582(15):2161-6. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/18519035.
  10. Abiko T, Sekino H. Synthesis of a thymosin beta 4-like peptide, deacetyl-thymosin beta Xen4, and its restorative effect on depressed lymphocyte blastogenic response to phytohemagglutinin (PHA) in uremic patients. Chemical & pharmaceutical bulletin. 1989; 37(9):2467-71. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/2605693.
  11. Low TL, Thurman GB, Chincarini C. Current status of thymosin research: evidence for the existence of a family of thymic factors that control T-cell maturation. Annals of the New York Academy of Sciences. 1979; 332:33-48. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/394636.
  12. Carion, T. W., Ebrahim, A. S., Alluri, S., Ebrahim, T., Parker, T., Burns, J., Sosne, G., & Berger, E. A. (2020). Antimicrobial Effects of Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy in Pseudomonas aeruginosa Induced Keratitis. International journal of molecular sciences, 21(18), 6840. https://doi.org/10.3390/ijms21186840.
  13. Shrivastava S, Srivastava D, Olson EN, DiMaio JM, Bock-Marquette I. Thymosin beta4 and cardiac repair. Annals of the New York Academy of Sciences. 2010; 1194:87-96. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20536454.
  14. Zhu J, Song J, Yu L. Safety and efficacy of autologous thymosin β4 pre-treated endothelial progenitor cell transplantation in patients with acute ST segment elevation myocardial infarction: A pilot study. Cytotherapy. 2016; 18(8):1037-42. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27288307.
  15. Crockford D. Development of thymosin beta4 for treatment of patients with ischemic heart disease. Annals of the New York Academy of Sciences. 2007; 1112:385-95. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/17947592.
  16. Kumar S, Gupta S. Thymosin beta 4 prevents oxidative stress by targeting antioxidant and anti-apoptotic genes in cardiac fibroblasts. PloS one. 2011; 6(10):e26912. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22046407.
  17. Retrieved from https://transmedcomms.biomedcentral.com/articles/10.1186/s41231-016-0008-y.
  18. Evans MA, Smart N, Dubé KN, et al. Thymosin β4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing. Nature communications. 2013;4:2081. doi:10.1038/ncomms3081. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22046407.
  19. Postrach J, Schmidt M, Thormann M. Adeno-associated viral vector 2.9 thymosin ß4 application attenuates rejection after heart transplantation: results of a preclinical study in the pig. Transplantation. 2014; 98(8):835-43. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25321165.
  20. Bock-Marquette, I., Saxena, A., White, M. D., Dimaio, J. M., & Srivastava, D. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466–472. https://doi.org/10.1038/nature03000.
  21. Kim J, Jung Y. Potential Role of Thymosin Beta 4 in Liver Fibrosis. Haybaeck J, ed. International Journal of Molecular Sciences. 2015;16(5):10624-10635. doi:10.3390/ijms160510624. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463665/.
  22. Jiang Y, Han T, Zhang Z-G, et al. Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease. Chronic Diseases and Translational Medicine. 2017;3(3):165-168. doi:10.1016/j.cdtm.2017.06.003. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643779/.
  23. Schirmacher P., Geerts A., Pietrangelo A., Dienes H.P., Rogler C.E. Hepatocyte growth factor/hepatopoietin a is expressed in fat-storing cells from rat liver but not myofibroblast-like cells derived from fat-storing cells. Hepatology. 1992;15:5–11. doi: 10.1002/hep.1840150103. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/1530788.
  24. Philp D, Kleinman HK. Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences. 2010; 1194:81-6. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20536453.
  25. Liang J., Cai W.J., Han T., Jing L., Ma Z., Gao Y. The expression of thymosin β4 in chronic hepatitis B combined nonalcoholic fatty liver disease. Medicine (Baltimore) 2016;95:e5763. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28033294.
  26. Mann J., Oakley F., Akiboye F., Elsharkawy A., Thorne A.W., Mann D.A. Regulation of myofibroblasttransdifferentiation by DNA methylation and mecp2: Implications for wound healing and fibrogenesis. Cell Death Differ. 2007;14:275–285. doi: 10.1038/sj.cdd.4401979. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/16763620.
  27. Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mechanisms of ageing and development. 2004; 125(2):113-5. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15037013.
  28. Malinda KM, Sidhu GS, Mani H. Thymosin beta4 accelerates wound healing. The Journal of investigative dermatology. 1999; 113(3):364-8. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/10469335.
  29. Ti D, Hao H, Xia L. Controlled release of thymosin beta 4 using a collagen-chitosan sponge scaffold augments cutaneous wound healing and increases angiogenesis in diabetic rats with hindlimb ischemia. Tissue engineering. Part A. 2015; 21(3-4):541-9. Retrieves from https://www.ncbi.nlm.nih.gov/pubmed/25204972.
  30. Kim S, Kwon J. Thymosin beta 4 improves dermal burn wound healing via downregulation of receptor of advanced glycation end products in db/db mice. Biochimicaetbiophysicaacta. 2014; 1840(12):3452-9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25230158.
  31. Available from https://clinicaltrials.gov/ct2/show/study/NCT00598871.
  32. Dunn, S. P., Heidemann, D. G., Chow, C. Y., Crockford, D., Turjman, N., Angel, J., Allan, C. B., & Sosne, G. (2010). Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4. Annals of the New York Academy of Sciences, 1194, 199–206. https://doi.org/10.1111/j.1749-6632.2010.05471.x.
  33. Kleinman, H. K., & Sosne, G. (2016). Thymosin β4 Promotes Dermal Healing. Vitamins and hormones, 102, 251–275. https://doi.org/10.1016/bs.vh.2016.04.005.
  34. Xu, T. J., Wang, Q., Ma, X. W., Zhang, Z., Zhang, W., Xue, X. C., Zhang, C., Hao, Q., Li, W. N., Zhang, Y. Q., & Li, M. (2013). A novel dimeric thymosin beta 4 with enhanced activities accelerates the rate of wound healing. Drug design, development and therapy, 7, 1075–1088. https://doi.org/10.2147/DDDT.S50183.
  35. Brady, R. D., Grills, B. L., Schuijers, J. A., Ward, A. R., Tonkin, B. A., Walsh, N. C., & McDonald, S. J. (2014). Thymosin β4 administration enhances fracture healing in mice. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 32(10), 1277–1282. https://doi.org/10.1002/jor.22686.
  36. Sosne G, Qiu P, Kurpakus-Wheater M. Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent. Clinical ophthalmology (Auckland, NZ). 2007;1(3):201-207. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25230158.
  37. Sosne G, Chan CC, Thai K. Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Experimental eye research. 2001; 72(5):605-8. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11311052.
  38. Dunn SP, Heidemann DG, Chow CY. Treatment of chronic nonhealingneurotrophic corneal epithelial defects with thymosin beta4. Annals of the New York Academy of Sciences. 2010; 1194:199-206. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20536469.
  39. Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H, Hazlett LD. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Experimental eye research. 2002; 74(2):293-9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11950239.
  40. Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAETM) model. Clinical Ophthalmology (Auckland, NZ). 2015;9:877-884. doi:10.2147/OPTH.S80954. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445951/.
  41. Zhang J, Zhang ZG, Morris D, et al. Neurological Functional Recovery After Thymosin Beta4 Treatment in Mice with Experimental Auto Encephalomyelitis. Neuroscience. 2009;164(4):1887-1893. doi:10.1016/j.neuroscience.2009.09.054. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2784109/.
  42. Cheng P, Kuang F, Zhang H, Ju G, Wang J. Beneficial effects of thymosin β4 on spinal cord injury in the rat. Neuropharmacology. 2014; 85:408-16. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/24937047.
  43. Goldstein AL, Kleinman HK. Advances in the basic and clinical applications of thymosin β4. Expert opinion on biological therapy. 2015; 15 Suppl 1:S139-45. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/26096726.
  44. Zhang, J., Zhang, Z. G., Li, Y., Lu, M., Zhang, Y., Elias, S. B., & Chopp, M. (2016). Thymosin beta4 promotes oligodendrogenesis in the demyelinating central nervous system. Neurobiology of disease, 88, 85–95. https://doi.org/10.1016/j.nbd.2016.01.010.
  45. Morris DC, Chopp M, Zhang L, Zhang ZG. Thymosin beta4: a candidate for treatment of stroke? Annals of the New York Academy of Sciences. 2010; 1194:112-7. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20536457.
  46. Morris DC, Chopp M, Zhang L, Lu M, Zhang ZG. Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience. 2010; 169(2):674-82. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20627173.
  47. Morris DC, Cui Y, Cheung WL. A dose-response study of thymosin β4 for the treatment of acute stroke. Journal of the neurological sciences. 2014; 345(1-2):61-7. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25060418.
  48. Morris DC, Zhang ZG, Zhang J, Xiong Y, Zhang L, Chopp M. Treatment of neurological injury with thymosin β4. Annals of the New York Academy of Sciences. 2012; 1269:110-6. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23045978.
  49. Henry Ford Health System. “Researchers propose novel new treatment of stroke, other neurological diseases.” ScienceDaily. ScienceDaily, 2 March 2015. Retrieved from https://www.sciencedaily.com/releases/2015/03/150302123301.htm.
  50. Xiong Y, Mahmood A, Meng Y. Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury. Annals of the New York Academy of Sciences. 2012; 1270:51-8. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23050817.
  51. Conte E, Genovese T, Gili E. Protective effects of thymosin β4 in a mouse model of lung fibrosis. Annals of the New York Academy of Sciences. 2012; 1269:69-73. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23045972.
  52. Wang L, Chopp M, Szalad A. Thymosin β4 promotes the recovery of peripheral neuropathy in type II diabetic mice. Neurobiology of disease. 2012; 48(3):546-55. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22922221.
  53. Zhu J, Su LP, Ye L, Lee KO, Ma JH. Thymosin beta 4 ameliorates hyperglycemia and improves insulin resistance of KK Cg-Ay/J mouse. Diabetes research and clinical practice. 2012; 96(1):53-9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22217673.
  54. Retrieved from https://www.google.com/patents/US4444757.
  55. Philp, D., Nguyen, M., Scheremeta, B., St-Surin, S., Villa, A. M., Orgel, A., Kleinman, H. K., & Elkin, M. (2004). Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 18(2), 385–387. https://doi.org/10.1096/fj.03-0244fje.
  56. Gao, X. Y., Hou, F., Zhang, Z. P., Nuo, M. T., Liang, H., Cang, M., Wang, Z. G., Wang, X., Xu, T., Yan, L. Y., Guo, X. D., & Liu, D. J. (2016). Role of thymosin beta 4 in hair growth. Molecular genetics and genomics: MGG, 291(4), 1639–1646. https://doi.org/10.1007/s00438-016-1207-y.
  57. Philp, D., St-Surin, S., Cha, H. J., Moon, H. S., Kleinman, H. K., & Elkin, M. (2007). Thymosin beta 4 induces hair growth via stem cell migration and differentiation. Annals of the New York Academy of Sciences, 1112, 95–103. https://doi.org/10.1196/annals.1415.009.
  58. Gao, X., Liang, H., Hou, F., Zhang, Z., Nuo, M., Guo, X., & Liu, D. (2015). Thymosin Beta-4 Induces Mouse Hair Growth. PloS one, 10(6), e0130040. https://doi.org/10.1371/journal.pone.0130040.
  59. Philp, D., Goldstein, A. L., & Kleinman, H. K. (2004). Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mechanisms of ageing and development, 125(2), 113–115. https://doi.org/10.1016/j.mad.2003.11.005.
  60. Dai, B., Sha, R. N., Yuan, J. L., & Liu, D. J. (2021). Multiple potential roles of thymosin β4 in the growth and development of hair follicles. Journal of cellular and molecular medicine, 25(3), 1350–1358. https://doi.org/10.1111/jcmm.16241.
  61. Dai, B., Sha, R. N., Yuan, J. L., & Liu, D. J. (2021). Multiple potential roles of thymosin β4 in the growth and development of hair follicles. Journal of cellular and molecular medicine, 25(3), 1350–1358. https://doi.org/10.1111/jcmm.16241.
  62. Cha, H. J., Philp, D., Lee, S. H., Moon, H. S., Kleinman, H. K., & Nakamura, T. (2010). Over-expression of thymosin beta 4 promotes abnormal tooth development and stimulation of hair growth. The International journal of developmental biology, 54(1), 135–140. https://doi.org/10.1387/ijdb.082735hc.
  63. Rinaldi, F., Marzani, B., Pinto, D., & Sorbellini, E. (2019). Randomized controlled trial on a PRP-like cosmetic, biomimetic peptides based, for the treatment of alopecia areata. The Journal of dermatological treatment, 30(6), 588–593. https://doi.org/10.1080/09546634.2018.1544405.